Bayer Expands Genetic Medicine Portfolio Through Strategic siRNA and AI Partnerships
Key Insights
Bayer has entered a global licensing agreement with Soufflé Therapeutics (search) to develop heart-targeted siRNA therapy for rare dilated cardiomyopathy (search), leveraging proprietary cell-selective delivery technology.
The company formed a three-year collaboration with Cradle (search) to integrate generative AI technology into its R&D workflows for accelerating therapeutic antibody development and optimization.
Bayer's AskBio subsidiary received FDA IND clearance for AB-1009 (search), an AAV gene therapy for late-onset Pompe disease (search), with phase I/II trials expected to begin patient recruitment in early 2026.
German pharmaceutical giant Bayer AG has significantly expanded its genetic medicine capabilities through two major strategic partnerships, positioning the company at the forefront of next-generation therapeutic modalities. The company entered into a collaboration and global licensing agreement with Soufflé Therapeutics (search) to develop heart-targeted small interfering RNA (siRNA) therapy for rare dilated cardiomyopathy (search), while simultaneously partnering with Cradle (search) to integrate artificial intelligence into its drug development processes.
Heart-Targeted siRNA Breakthrough
The collaboration with Soufflé Therapeutics (search) addresses one of the most challenging aspects of genetic medicine: precise delivery to target tissues. Soufflé Therapeutics brings a proprietary platform designed to enable cell-selective delivery of siRNA therapies, with the ability to engineer cell-specific ligands that transport siRNA directly into heart cells. This targeted approach could reduce off-target effects and decrease the need for frequent dosing, addressing significant limitations in current therapeutic approaches.
The partnership focuses on advancing a siRNA-based treatment for a rare form of dilated cardiomyopathy (search), a condition with limited therapeutic options. The agreement deepens Bayer's relationship with Soufflé beyond its initial investment through Leaps by Bayer, demonstrating the company's commitment to bolstering its cardiovascular portfolio while entering the fast-evolving siRNA space.
AI-Powered Drug Development
Bayer's strategic collaboration with Cradle (search) represents a three-year commitment to deploy advanced AI technology in protein engineering. Under this agreement, Bayer will integrate Cradle's generative AI technology into its existing R&D workflows to accelerate lead generation and optimization across its therapeutic antibody pipeline.
The AI platform is designed to help advance higher-quality molecules into clinical development more quickly by reducing optimization cycles, enhancing molecular potency, safety and manufacturability, and increasing the probability of technical success as the company pursues more complex mechanisms of action. Cradle (search) will provide Bayer's antibody scientists with full access to its AI software platform, supporting integrated design-test-learn cycles and coordinated execution across internal laboratories and external partners.
Gene Therapy Advances
Bayer's AskBio subsidiary achieved a significant regulatory milestone with FDA acceptance of its investigational new drug (IND) application for AB-1009 (search), an adeno-associated virus (AAV) gene therapy being developed for late-onset Pompe disease (search) (LOPD). AskBio operates as a wholly owned subsidiary of Bayer, focusing exclusively on gene therapy development.
With IND clearance, the program has advanced into a phase I/II study in the United States, with AskBio anticipating recruitment of its first patient in early 2026. The therapy has received both Fast Track and Orphan Drug designations from the FDA, reflecting the significant unmet medical need in this patient population.
Pompe disease is a rare, progressive and debilitating genetic disorder affecting an estimated 5,000 to 10,000 patients worldwide. The disease represents a significant therapeutic challenge, making the development of AB-1009 (search) particularly important for the affected patient community.
Recent Regulatory Successes
Bayer's pipeline momentum extends beyond genetic medicines, with several recent regulatory approvals demonstrating the company's diversified therapeutic approach. The FDA recently approved elinzanetant for the treatment of moderate to severe menopause-related vasomotor symptoms (search) under the brand name Lynkuet. The drug has also received approval from the European Commission and was previously approved in the UK.
Additionally, the FDA granted accelerated approval to Hyrnuo (search) (sevabertinib (search)) for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (search) whose tumors have human epidermal growth factor receptor 2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
Pipeline Progress and Market Performance
Bayer continues to advance multiple pipeline candidates across various therapeutic areas. The company's investigational contrast agent gadoquatrane has been accepted for review in both the United States and China for use in contrast-enhanced magnetic resonance imaging of the central nervous system and other body regions in adults and pediatric patients.
The company also achieved positive results with asundexian, which met primary efficacy and safety endpoints in the late-stage OCEANIC-STROKE Study for secondary stroke prevention. Bayer plans to work with health authorities worldwide to submit marketing authorization applications for this candidate.
Earlier this week, both the FDA and China's Center for Drug Evaluation granted Breakthrough Therapy Designation to sevabertinib (search) as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (search) with HER2 (search) activating mutations.
These strategic partnerships and regulatory achievements have contributed to Bayer's impressive market performance, with the stock surging 123.7% over the past year, significantly outpacing the industry's growth of 20.9%. The company's expansion into new therapeutic modalities through acquisitions like BlueRock for cell therapy and AskBio for gene therapy positions Bayer as a comprehensive player in next-generation medicine development.